EPZ015666 (GSK3235025), a PRMT5 inhibitor, further demonstrated significant antiproliferative effects against MCL in vitro and in vivo [148] and also slowed down the proliferation of DLBCL cells [150]. The gene discussed is PRMT5; the disease is diffuse large B-cell lymphoma.